Dara Biosciences Inc (NASDAQ:DARA)

CAPS Rating: 2 out of 5


Player Avatar whoodatstockhot (82.98) Submitted: 1/29/2013 12:34:58 PM : Outperform Start Price: $5.00 DARA Score: -28.11

Exciting pipeline-- DRN5500 fastracked, successful phase2a trial-- for treatmentment of neurpathy-- potential blackbuster. Also, DB959 will be out-licensed should bring in some good revenue. On top of that DARA has marketing rights to Soltamox for treatment of breast cancer, and has already launched Bionect for burns associated with radiation therapy. Absurdly cheap on valuation basis-- could see $2.00 in no time. Long-term much higher Worth a caps pick.

Featured Broker Partners